20
26Half-year
Report
Creating the future in peptides
Editorial
“In the first half of 2026, we delivered 42% growth, entered into a transformational transaction agreement with Samsung Biologics, and raised our full-year guidance.”
Peter Wilden
Chair of the Board of Directors
Juan Jose Gonzalez
Chief Executive Officer
Highlights
Revenue
€m236.6
+41.6%
EBITDA
€m49.1
20.7% of revenue
Capital expenditures
€m41.3
17.5% of revenue
)
)
)
)
)
)